-
-
-
-
-
-
-
eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent
-
-
-
-
-
-
-
eFFECTOR Therapeutics and Locust Walk Acquisition (LWAC) Announce Merger Agreement
-
-
1,157,776 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

